Astec LifeSciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astec LifeSciences, a Godrej-group agrochemical company, reported Q1 FY26 results with revenue from operations rising 31% year-on-year to Rs 9,108.21 lakh from Rs 6,937.25 lakh. Despite the revenue growth, the company posted a standalone net loss of Rs 3,305.64 lakh, although this was narrower than the Rs 3,973.69 lakh loss in Q1 FY25. Operating margin improved sharply from -66.67% to -12.06%, and net loss margin also narrowed from -57.28% to -36.29%. However, key financial health metrics are weak: debt-equity ratio has climbed to 2.96 (from 1.58 a year ago), debt service coverage and interest coverage ratios are negative, current ratio is 0.78 with negative working capital. The statutory auditor (BSR & Co. LLP) issued an unmodified review opinion. A Rs 249.35 crore rights issue at Rs 890 per share (1:7 ratio) is currently open and closes on the same day (July 28, 2025).
The strong revenue growth and improving margins signal a business recovery, but persistent losses, surging leverage (D/E of 2.96), and negative debt service coverage keep the stock risky. The rights issue outcome is critical — proceeds are needed to shore up the balance sheet. Short-term stock movement is likely to depend heavily on rights issue subscription levels.